| MDL | - |
|---|---|
| Molecular Weight | 204.31 |
| Molecular Formula | C14H20O |
| SMILES | CC(C1=CC=CC([C@@H](C2CC2)C)=C1O)C |
Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABA A receptor . Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol ( HY-B0649 ). Cipepofol can activate the sirtuin1 (Sirt1)/Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468)-induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis [1] [2] .
Cipepofol (Ciprofol) can trigger chloride influx by competitive binding to butylbicyclophosphorothionate and t-butylbicycloorthobenzoate targets in the chloride channels of GABAA receptors. The influx of chloride can cause hyperpolarization of nerve cell membranes by increasing the intracellular chloride concentration and further activating GABAergic neurons to achieve central nerve inhibition
[1]
.
Cipepofol (5 μM before ISO insult for 6 h) blunts the contents of CK-MB, LDH and cTnT were increased in ISO-treated H9c2 cells. Cipepofol attenuates ISO-induced cardiomyocyte
apoptosis
in vitro
[2]
.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cipepofol (Ciprofol; 100 μL; implanted into the abdomen of mice 1 h before ISO) suppresses ISO-induced myocardial damage, cardiac dysfunction, and inflammation and cardiomyocyte
apoptosis
[2]
.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Eighty male C57BL/6 mice (20-24 g, 8-10 weeks) [2] |
| Dosage: | 100 μl |
| Administration: | Implanted into the abdomen of mice 1 h before ISO |
| Result: |
Attenuated increased the content of serum CK-MB, LDH, and cTnT by ISO insults (100 mg/kg; sc; for 2 consecutive days to induce experimental myocardial infarction).
Significantly improved ISO-induced LV systolic and diastolic dysfunction. Largely suppressed the increases in IL-6 IL-17 and TNF-α expression. |
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04294056 | Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia
|
May 26, 2020 | Phase 1 |
| NCT04147416 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Sedation
|
November 22, 2019 | Phase 2 |
| NCT03745625 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
January 9, 2019 | Phase 1 |
| NCT03751956 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
January 6, 2019 | Phase 1 |
| NCT04145596 | Sichuan Haisco Pharmaceutical Group Co., Ltd|The First Hospital of Jilin University|Haisco Pharmaceutical Group Co., Ltd. |
Hepatic Impairment
|
November 14, 2019 | Phase 1 |
| NCT04037657 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
April 22, 2015 | Phase 1 |
| NCT05294679 | Sichuan Provincial People´s Hospital |
Induction of Anaesthesia
|
June 1, 2022 | Not Applicable |
| NCT04511728 | Haisco Pharmaceutical Group Co., Ltd. |
Induction and Maintenance of General Anesthesia
|
November 24, 2020 | Phase 3 |
| NCT03709056 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Sedation and Anesthesia for Adult Colonoscopy Procedures
|
December 14, 2017 | Phase 2 |
| NCT04197661 | Sichuan Haisco Pharmaceutical Group Co., Ltd|The First Hospital of Jilin University|Haisco Pharmaceutical Group Co., Ltd. |
Healthy Elderly Subjects
|
December 25, 2019 | Phase 1 |
| NCT04958746 | Haisco Pharmaceutical Group Co., Ltd. |
Gynecological Outpatient Surgery
|
July 26, 2021 | Phase 3 |
| NCT03773042 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Colonoscopy
|
December 2016 | Phase 2 |
| NCT04145583 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
December 14, 2019 | Phase 1 |
| NCT03808844 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Induction of Anesthesia
|
March 22, 2019 | Phase 3 |
| NCT05518929 | RenJi Hospital|Zhejiang Cancer Hospital|Beijing Hospital|Shenzhen People´s Hospital|Second Hospital of Shanxi Medical University |
Gastric Ulcer|Gastric Cancer|Gastrointestinal Polyp
|
September 8, 2022 | Phase 4 |
| NCT03698617 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Induction of General Anaesthesia
|
December 6, 2016 | Phase 2 |
| NCT05486416 | Haisco-USA Pharmaceuticals, Inc. |
General Anesthesia
|
October 9, 2023 | Phase 3 |
| NCT05892471 | Le Yu|Shanghai East Hospital of Tongji University |
Anesthesia
|
August 1, 2022 | Not Applicable |
| NCT04958382 | Sichuan Provincial People´s Hospital |
Chronic Insomnia
|
December 1, 2021 | Not Applicable |
| NCT04033939 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
April 13, 2014 | Phase 1 |
| NCT04048811 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Induction and Maintenance of General Anesthesia
|
December 9, 2019 | Phase 2 |
| NCT04142970 | Sichuan Haisco Pharmaceutical Group Co., Ltd|The First Affiliated Hospital of Zhengzhou University|Haisco Pharmaceutical Group Co., Ltd. |
Chronic Renal Impairment
|
January 5, 2020 | Phase 1 |
| NCT05517408 | RenJi Hospital |
Gastric Cancer|Gastric Ulcer|Intestinal Polyps|Intestinal Cancer
|
September 19, 2022 | Not Applicable |
| NCT03773835 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
May 2016 | Phase 1 |
| NCT05881291 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Hemodynamics|Transcatheter Aortic Valve Replacement|General Anesthesia|Post-induction Hypotension
|
June 29, 2023 | Not Applicable |
| NCT05706337 | Xiumei Song|Qianfoshan Hospital |
Anesthesia|Pain|Hemodynamic Instability
|
February 1, 2023 | Phase 4 |
| NCT04669821 | Haisco Pharmaceutical Group Co., Ltd. |
Sedation in Intensive Care
|
March 9, 2021 | Phase 2 |
| NCT04620031 | Haisco Pharmaceutical Group Co., Ltd. |
Sedation in Intensive Care
|
December 8, 2020 | Phase 3 |
| NCT04029766 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
November 10, 2015 | Phase 1 |
| NCT05478174 | Haisco-USA Pharmaceuticals, Inc. |
General Anesthesia
|
July 26, 2022 | Phase 3 |
| NCT05035069 | Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia, General
|
September 3, 2021 | Phase 4 |
| NCT05266560 | First Affiliated Hospital of Chongqing Medical University |
Depressive Disorder
|
March 1, 2022 | Early Phase 1 |
| NCT03758469 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
December 14, 2018 | Phase 1 |
| NCT03751969 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Anesthesia|Sedation
|
March 30, 2020 | Phase 1 |
| NCT05971121 | Nanfang Hospital, Southern Medical University |
Ciprofol|Propofol|Sedation|Low Blood Pressure|Norepinephrine
|
October 1, 2022 | |
| NCT05664386 | Xiumei Song|Qianfoshan Hospital |
Hemodynamics|Postoperative Recovery|Anesthesia
|
April 10, 2023 | Phase 4 |
| NCT05614544 | Haisco-USA Pharmaceuticals, Inc. |
General Anesthesia
|
August 16, 2022 | Phase 1 |
| NCT04111159 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Sedation or Anesthesia
|
December 6, 2019 | Phase 3 |
| NCT05843383 | Xijing Hospital |
Anesthetics, Intravenous|Postoperative Complications|Hypnotics and Sedatives|Postoperative Recovery
|
May 16, 2023 | Not Applicable |
| NCT05522998 | The Third People´s Hospital of Chengdu |
Bariatric Surgery
|
January 1, 2023 | Phase 4 |
| NCT04711837 | Haisco-USA Pharmaceuticals, Inc. |
Anesthesia
|
February 11, 2021 | Phase 3 |
| NCT03674008 | Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd. |
Sedation or Anesthesia
|
October 9, 2018 | Phase 3 |
Liquid
Room temperature in continental US; may vary elsewhere.
| Pure form | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 100 mg/mL ( 489.45 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.8945 mL | 24.4726 mL | 48.9452 mL |
| 5 mM | 0.9789 mL | 4.8945 mL | 9.7890 mL |
| 10 mM | 0.4895 mL | 2.4473 mL | 4.8945 mL |